Skip to main content
Midas Edge

10x Genomics Inc

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 13, 2025

TXG$62.90-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 2021112,514,977$2$1,680,865$(863,321)$22$817,568
Issuance of Class A common stock related to equity awards2,680,032—21,226——21,226
Vesting of shares subject to repurchase, including early exercised options——96——96
Stock-based compensation——137,210——137,210
Net loss———(166,000)—(166,000)
Other comprehensive loss————(4,357)(4,357)
Balance as of December 31, 2022115,195,00921,839,397(1,029,321)(4,335)805,743
Issuance of Class A common stock related to equity awards3,900,353—19,483——19,483
Stock-based compensation——167,010——167,010
Net loss———(255,099)—(255,099)
Other comprehensive income————3,9063,906
Balance as of December 31, 2023119,095,36222,025,890(1,284,420)(429)741,043
Issuance of Class A common stock related to equity awards3,196,475—10,914——10,914
Stock-based compensation——140,868——140,868
Net loss———(182,627)—(182,627)
Other comprehensive loss————(64)(64)
Balance as of December 31, 2024122,291,837$2$2,177,672$(1,467,047)$(493)$710,134

The accompanying notes are an integral part of these consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.